Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Hemolytic Transfusion Reactions.

Strobel E.

Transfus Med Hemother. 2008;35(5):346-353. Epub 2008 Sep 18.

2.

Potent inhibition of the classical pathway of complement by a novel C1q-binding peptide derived from the human astrovirus coat protein.

Gronemus JQ, Hair PS, Crawford KB, Nyalwidhe JO, Cunnion KM, Krishna NK.

Mol Immunol. 2010 Nov-Dec;48(1-3):305-13. doi: 10.1016/j.molimm.2010.07.012. Epub 2010 Aug 21.

PMID:
20728940
3.

Human astrovirus coat protein binds C1q and MBL and inhibits the classical and lectin pathways of complement activation.

Hair PS, Gronemus JQ, Crawford KB, Salvi VP, Cunnion KM, Thielens NM, Arlaud GJ, Rawal N, Krishna NK.

Mol Immunol. 2010 Jan;47(4):792-8. doi: 10.1016/j.molimm.2009.10.006. Epub 2009 Nov 6.

PMID:
19896716
4.

Analogous interactions in initiating complexes of the classical and lectin pathways of complement.

Phillips AE, Toth J, Dodds AW, Girija UV, Furze CM, Pala E, Sim RB, Reid KB, Schwaeble WJ, Schmid R, Keeble AH, Wallis R.

J Immunol. 2009 Jun 15;182(12):7708-17. doi: 10.4049/jimmunol.0900666.

5.

Compstatin: a complement inhibitor on its way to clinical application.

Ricklin D, Lambris JD.

Adv Exp Med Biol. 2008;632:273-92. Review.

6.

The changing face of haemolytic disease of the newborn.

Roberts IA.

Early Hum Dev. 2008 Aug;84(8):515-23. doi: 10.1016/j.earlhumdev.2008.06.005. Epub 2008 Jul 14. Review.

PMID:
18621490
7.

Clinical outcomes of ABO-incompatible RBC transfusions.

Janatpour KA, Kalmin ND, Jensen HM, Holland PV.

Am J Clin Pathol. 2008 Feb;129(2):276-81. doi: 10.1309/VXY1ULAFUY6E6JT3.

PMID:
18208808
8.

Complement-targeted therapeutics.

Ricklin D, Lambris JD.

Nat Biotechnol. 2007 Nov;25(11):1265-75. Review.

9.

Human astrovirus coat protein inhibits serum complement activation via C1, the first component of the classical pathway.

Bonaparte RS, Hair PS, Banthia D, Marshall DM, Cunnion KM, Krishna NK.

J Virol. 2008 Jan;82(2):817-27. Epub 2007 Oct 24.

10.

Human neutrophil peptide-1 inhibits both the classical and the lectin pathway of complement activation.

Groeneveld TW, Ramwadhdoebé TH, Trouw LA, van den Ham DL, van der Borden V, Drijfhout JW, Hiemstra PS, Daha MR, Roos A.

Mol Immunol. 2007 Jul;44(14):3608-14. Epub 2007 Apr 19.

PMID:
17448537
11.

Single versus double volume exchange transfusion in jaundiced newborn infants.

Thayyil S, Milligan DW.

Cochrane Database Syst Rev. 2006 Oct 18;(4):CD004592. Review.

PMID:
17054210
12.

Self, non-self, and danger: a complementary view.

Köhl J.

Adv Exp Med Biol. 2006;586:71-94. Review.

PMID:
16893066
13.

Immune hemolysis-serological and clinical aspects.

Pruss A, Salama A, Ahrens N, Hansen A, Kiesewetter H, Koscielny J, Dörner T.

Clin Exp Med. 2003 Sep;3(2):55-64. Review.

PMID:
14598182
14.

Specific inhibition of the classical complement pathway by C1q-binding peptides.

Roos A, Nauta AJ, Broers D, Faber-Krol MC, Trouw LA, Drijfhout JW, Daha MR.

J Immunol. 2001 Dec 15;167(12):7052-9.

15.

Capsule production and growth phase influence binding of complement to Staphylococcus aureus.

Cunnion KM, Lee JC, Frank MM.

Infect Immun. 2001 Nov;69(11):6796-803.

16.
17.

Further characterization of the interaction between the C1q subcomponent of human C1 and the transmembrane envelope glycoprotein gp41 of HIV-1.

Thielens NM, Bally IM, Ebenbichler CF, Dierich MP, Arlaud GJ.

J Immunol. 1993 Dec 1;151(11):6583-92.

PMID:
8245486

Supplemental Content

Support Center